V V Naydenova

Togliatti City Clinical Hospital No 2 named after V.B. Banykina, Togliatti, Russia.

2 publications 2015 – 2025 ORCID
RussiaIschemic StrokeFibrinolytic AgentsTissue Plasminogen ActivatorThrombolytic Therapy

What does V V Naydenova research?

V V Naydenova studies ischemic stroke, which occurs when blood flow to the brain is blocked. They specifically research the medication Revelise, which is used to dissolve blood clots in patients experiencing this type of stroke. Their work involves analyzing real-life outcomes for patients treated with Revelise, especially older individuals and those with other health problems, to understand how well this treatment works in everyday medical practice.

Key findings

  • In a study involving 2,202 patients, 49.9% showed good outcomes when discharged after treatment with Revelise.
  • The percentage of patients who had good outcomes increased to 66.4% after 90 days.
  • Revelise effectively reduces stroke-related disabilities even in older patients and those with additional health issues.

Frequently asked questions

Does Dr. Naydenova study ischemic stroke?
Yes, Dr. Naydenova focuses specifically on ischemic stroke and its treatments.
What treatment has Dr. Naydenova researched?
Dr. Naydenova has researched the medication Revelise for treating ischemic stroke.
Is Dr. Naydenova's work relevant to older stroke patients?
Yes, their research shows favorable outcomes with Revelise even for older patients and those with other health challenges.

Publications in plain English

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

[ACUTE KIDNEY INJURY AND IN-HOSPITAL MORTALITY IN PATIENTS WITH STROKE].

2015

Klinicheskaia meditsina

Gerdt AM, Shutov AM, Menzorov MV, Naydenova VV

Plain English
This study looked at how often acute kidney injury (AKI) occurs in stroke patients and its effect on their chances of dying in the hospital. Out of 180 patients, 27.3% had AKI, and those patients were 2.5 times more likely to die during their hospital stay compared to those without AKI. This matters because it highlights the serious risks associated with kidney injury in stroke patients and suggests that monitoring kidney function could be critical for improving patient outcomes. Who this helps: This helps patients who have had a stroke, as well as their doctors.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.